AtriCure’s (ATRC) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $46.00 target price on the medical device company’s stock. ATRC has been the topic of a number of other reports. StockNews.com lowered shares of AtriCure […]
More Stories
Democrats Sue Trump Admin Over Bid to Clean Up Voter Rolls
By Zachary Stieber Senate Minority Leader Chuck Schumer (D-N.Y.) and other Democrats have sued the Trump administration over its effort...
Implementing Freight Management Software: In-House or With Specialist Help?
You’ve picked a freight platform. Now you have to get it live without stopping trucks, missing invoices or losing track...
DOGE Illegally Accessed Data on Government Workers: Judge
By Zachary Stieber A federal judge ruled on Oct. 20 that a department aimed at making the government more efficient...
UK Rearrests 2 Men Over Suspected Terror Plot at Air Base
By Jill McLaughlin UK police have rearrested two men, suspected of working for Iran’s intelligence service, for allegedly plotting to...
$245 Million Taxpayer-Backed Loan to Fund Naval Shipbuilding Facilities
By AAP Australia will lend hundreds of millions of dollars to the nation’s largest shipbuilder for a massive new manufacturing...
Music Publishers Sue Anthropic for Copyright Infringement
By Stacy Robinson A federal district court in California is set to hear arguments this week as a group of...